Investor's Business Daily on MSN33m
Novo Nordisk Dives 9%. Why Eli Lilly Now Has The Upper Hand.Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.
Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback